High-Dose, Extended Duration Aflibercept Injections Benefit Patients With DME, nAMD
October 3rd 2022Results from the pivotal PHOTON and PULSAR trials highlighted the success of 8-mg aflibercept every 12 or 16 weeks in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
Read More
Dr Richard Allen Speaks on the Evolution of Oculoplastic Surgery for Children
October 3rd 2022Richard C. Allen, MD, PhD, FACS, an oculoplastic surgeon at Texas Children's Hospital and a professor at Baylor College of Medicine, spoke on how oculoplastic surgery in pediatric patients has changed at the American Academy of Ophthalmology's 2022 conference.
Watch
In AAO Lecture, AMA CEO Discusses How the Organization Is Addressing Areas of Innovation
October 3rd 2022During a lecture delivered at the American Academy of Ophthalmology (AAO) annual meeting, James Madara, MD, CEO of the American Medical Association, discussed 3 areas in ophthalmology care that required innovation to effectively push care into the 21st century.
Read More
T&E Regimen, Consistent Adherence Important to Management of nAMD
October 2nd 2022Posters presented at the American Academy of Ophthalmology 2022 annual meeting show that the treat-and-extend (T&E) regimen was effective in managing neovascular age-related macular degeneration (nAMD), which makes adherence to treatment vital for long-term outcomes.
Read More
Dr Michael Chiang Chronicles the NEI's Research Into AI, Telemedicine in Ophthalmology
October 2nd 2022Advances in imaging and data science are changing the nature of retina practice, and retina specialists need to stay on top of these, said Michael F. Chiang, MD, director of the National Eye Institute (NEI), who also discussed some of the current research the agency is conducting into artificial intelligence (AI) and telemedicine.
Watch
Dr Michel Michaelides Dives Into How Gene Therapy Can Treat Retinitis Pigmentosa
October 2nd 2022Gene therapy can be used to treat retinitis pigmentosa, an inherited eye disease, and there is likely to be an increase in approved gene therapies for ophthalmic conditions, explained Michel Michaelides, MD, FACP, a consultant ophthalmologist and a professor of ophthalmology at the University College London Institute of Ophthalmology's Genetics Department.
Watch
Which DME Drug to Try First? Patients on Bevacizumab Can Successfully Transition to Aflibercept
October 2nd 2022The presentation focused on the Protocol AC trial, which considered whether step therapy had an impact on visual outcomes for patients starting on bevacizumab and switching to aflibercept later.
Read More
Dr Ravi Goel Discusses the Future of Technology in Ophthalmic Practice
October 1st 2022The ophthalmology practice of the future will need to manage patients more efficiently and that means incorporating more technology, said Ravi Goel, MD, spokesperson for the AAO and ophthalmologist at Regional Eye Associates in New Jersey.
Watch
Posters Emphasize Prevalence and Need for Prompt Treatment of RVO
September 30th 2022Posters presented at the American Academy of Ophthalmology 2022 annual meeting showed that patients with retinal vein occlusion (RVO) are most likely older with higher diastolic blood pressure, and they require prompt treatment to help manage the disease.
Read More
AAO Panel Offers Insight on Treatment Recommendations, In-Office Retina Surgery
September 30th 2022Speakers at a panel at the American Academy of Ophthalmology (AAO) 2022 conference spoke about future treatment options for patients in both minimally proven operations and in-office retina surgeries.
Read More
Dr Grayson Armstrong Highlights How Ophthalmologists Are Early Adopters of Innovation
September 27th 2022Ophthalmology is image heavy, which has made the specialty amenable to telemedicine and the implementation of artificial intelligence, said Grayson Armstrong, MD, medical director, ophthalmic emergency services at Massachusetts Eye and Ear, and instructor in ophthalmology at Harvard Medical School.
Watch
AMA’s Dr James Madara to Discuss Precompetitive Positions and Innovation Needs at AAO
September 26th 2022During the Parker Heath Lecture at the American Academy of Ophthalmology (AAO) annual meeting, James Madara, MD, CEO of the American Medical Association (AMA), will discuss the 3 arcs of the AMA’s strategic framework and the innovation that needs to occur.
Watch
Dr Ravi Goel Previews Session on Innovations and Closing Presentation at AAO
September 26th 2022The American Academy of Ophthalmology (AAO) annual meeting will present cutting-edge topics on retinal disease, as well as feature a presentation from historian Doris Kearns Goodwin, said Ravi Goel, MD, spokesperson for AAO and ophthalmologist at Regional Eye Associates in New Jersey.
Watch
Dr Hatim Husain Discusses HER2, Novel Therapy Exploration in Lung Cancer
September 23rd 2022During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.
Watch
Dr Anchalee Avihingsanon: We Can Learn About Curing Hepatitis B From Investigating HIV
September 10th 2022Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial, currently evaluating the responses of treatment-naïve persons living with comorbid HIV/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.
Watch
Dr Anchalee Avihingsanon: We Need More Study on Hep B Endurance in PLWH
September 3rd 2022The ALLIANCE trial is investigating the responses of treatment-naïve persons living with comorbid HIV (PLWH)/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.
Watch
Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC
August 29th 2022Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.
Watch
SGLT2 Inhibitors, Combination Therapy Needed to Stem the Tide of CKD in Diabetes
August 20th 2022Katherine R. Tuttle, MD, FASN, FACP, FNKF, a nephrologist from the University of Washington and Providence Health Care, discussed new consensus guidelines that call for the early use of sodium glucose cotransporter 2 (SGLT2) inhibitors, GLP-1 receptor agonists, and finerenone in the care of patients with both chronic kidney disease (CKD) and diabetes.
Read More
QCCA Panel Highlights Expansion of Innovation at Independent Community Oncology
August 17th 2022Value management, theranostics, clinical trial access, and a mobile pharmacy are major innovations being integrated into independent community oncology practices, as highlighted at the Quality Cancer Care Alliance Summer 2022 National Leadership Summit.
Read More
As Health Disparities “Weave Their Way Through Hypertension,” New Agents Are on the Way
August 8th 2022Coverage from the 2022 Congress of the American Society for Preventive Cardiology (ASPC) in Louisville, Kentucky, featuring 3 experts on aspects of hypertension treatment: Keith C. Ferdinand, MD, of Tulane University School of Medicine; Kim Allan Williams, MD, of the University of Louisville; and George C. Bakris, MD, of the University of Chicago Medicine.
Read More
Cardiologists Must “Get Into the Game” With Novel Agents in Patients With Diabetes
August 3rd 2022During the 2022 Congress of the American Society for Preventive Cardiology (ASPC), held in Louisville, Kentucky, Erin D. Michos, MD, MHS, of Johns Hopkins, and Pam R. Taub, MD, of UC San Diego Health, discussed how treatment of diabetes requires going beyond glucose-lowering therapies and including newer medications that offer cardiovascular benefits.
Read More
Gulati on Unequal CV Treatment for Women: “There Is a Bias in Our Care”
August 1st 2022Martha Gulati, MD, MS, kicked off the symposium “Saving the Hearts of Women Through Prevention” ahead of the 2022 Congress of the American Society for Preventive Cardiology, which took place Friday through Sunday in Louisville, Kentucky.
Read More
Social Determinants, Including Racism, Are Major Drivers of Health Inequity, Watson Says
July 31st 2022Social determinants of health are major drivers of the inequities seen in health outcomes, and racism is clearly a social determinant tied to life expectancy, said Karol Watson, MD, PhD, in talk Sunday at the 2022 Congress of the American Society for Preventive Cardiology, held in Louisville, Kentucky.
Read More
Gluckman Calls for Better Data, Payer Policies to Drive Value-Based CV Care
July 30th 2022Ty J. Gluckman, MD, FACC, FAHA, who is medical director of the Center for Cardiovascular Analytics, Research, and Data Science at Providence St. Joseph Health in Portland, Oregon, addressed the 2022 Congress of the American Society for Preventive Cardiology meeting in Louisville, Kentucky.
Read More